Multibagger Selection: DeepSeek's picks
DeepSeek picked AQST, CRMD, MLYS, IMNM, ACHR with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | AQST | — | 72% | — | — |
| 2 | CRMD | — | 70% | — | — |
| 3 | MLYS | — | 68% | — | — |
| 4 | IMNM | — | 65% | — | — |
| 5 | ACHR | — | 62% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -12.84% | -11.91% | 1.22x | 0 |
The model's market view
The current environment for small and mid-cap multibagger candidates is constructive but highly selective. Biotech names with hard-dated FDA catalysts offer binary but time-bound upside, while select technology and infrastructure names with visible revenue inflection and adequate liquidity are attracting capital. The reverse-valuation test remains demanding: only companies with credible paths to step-change revenue and earnings can justify 3x market-cap expansion within 12 months without relying on unrealistic multiples.
Why each pick
AQST
Aquestive Therapeutics is a late-clinical specialty pharma with a hard-dated FDA catalyst. The company received FDA acceptance for the Anaphylm NDA resubmission, with a PDUFA target action date of March 16, 2027. Anaphylm is a sublingual epinephrine film for anaphylaxis, a large unmet need currently dominated by injectable epinephrine. A favorable approval would transform the revenue base from roughly $54 million TTM to a potential multi-hundred-million-dollar franchise. The market cap of about $511 million is small relative to the addressable epinephrine market, and the stock trades well below its 52-week high. The binary regulatory event is the dominant driver, but the setup is unusually clean for a 12-month multibagger candidate.
CRMD
CorMedix is a commercial-stage pharmaceutical company with a profitable base business and a near-term label-expansion catalyst. The company reported Q2 2026 consolidated revenue of $101.9 million (+157% YoY) and strong EBITDA generation of $58.7 million, with $256.7 million in cash. The FDA has accepted a supplemental NDA for Rezzayo for the prophylaxis of invasive fungal disease and granted Priority Review, with a PDUFA target action date in Q1 2027. The market cap of roughly $600 million is supported by an already profitable business, making the 3x scenario less dependent on a single binary event than pure clinical-stage biotech names.
MLYS
Mineralys Therapeutics is a clinical-stage biotech with a near-term, high-value FDA catalyst. The company’s lead candidate lorundrostat is in development for uncontrolled hypertension, a large market with significant unmet need. The FDA PDUFA date for lorundrostat is December 22, 2026, making it one of the nearest binary catalysts among small-cap biotech names. The market cap of ~$1.87 billion reflects some probability of approval, but a successful launch could support a substantially larger revenue base. The stock has pulled back from its highs, improving the risk/reward for a 12-month window.
IMNM
Immunome is a clinical-stage oncology company with a hard-dated FDA catalyst. The company’s lead program has a PDUFA target action date of April 28, 2027. The market cap of ~$2.1 billion is supported by a strong cash position of ~$520 million and a pipeline that includes multiple oncology assets. The binary nature of the catalyst creates a wide range of outcomes, but the reverse-valuation path to 3x is feasible if the lead asset is approved and commercialized successfully.
ACHR
Archer Aviation is a pre-commercial eVTOL leader with a specific, time-bound catalyst: FAA type certification and the start of commercial passenger operations. Archer has said it is in the fourth and final phase of the FAA type-certification process and targets certification and commercial launch by late 2027. The company ended Q2 2026 with $1.6 billion in liquidity and is building out manufacturing and operations. The market cap of ~$3.1 billion is supported by the long-term air-taxi opportunity, but the 12-month window captures the certification and launch milestones. The reverse-valuation path to 3x is ambitious but not economically impossible if certification is achieved and early commercial traction is credible.
Other models on the same run
| Model | Picks |
|---|---|
| Perplexity | LIFE, DAVE, PGY, MAZE, FOUR |
| Gemini 3.6 Flash High | AEHR, SOUN, SKYT, MGNI, SERV |
| Claude Sonnet 5.5 | AEHR, FCEL, ETON, NVTS, FSLY |
| Muse Spark 1.1 | INOD, UPST, SVRA, BASE, RGTI |
| GPT-6 | PGY, ARDX, INOD, FLNC, BKSY |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.